Cerba Research has conducted ~80 hematological malignancy trials within the last 5 years alone. Download our fact sheet and discover our hematological malignancies trial portfolio with cutting-edge laboratory solutions.

Cerba Research offers specialized HPV SPF10 PCR-detection/typing kits tailored to detect and identify HPV genotypes in vaccine and epidemiology studies. Our HPV vaccine research capabilities ensure comprehensive analysis and accurate identification of relevant genotypes. Take a look at our brochure and discover how our assay excels in analyzing HPV in formalin-fixed-paraffin embedded (FFPE) tissues, facilitating a correlation between histological findings and specific HPV genotypes.

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. The central and specialty laboratories’ expertise includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), AI in image analysis, and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Experience the unparalleled activity of Cerba Research’s Infectious Diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years.

ENPICOM and Cerba Research have joined forces to conduct an in-depth interview focused on the applications, challenges, and future prospects within the realm of full-service repertoire sequencing.

In this collaborative effort, our esteemed experts, Dirk van Alewijk, PhD, Goran and Ilse Wolters, and Henk-Jan van den Ham from ENPICOM, provide insights about the challenges of analyzing repertoire data, promising repertoire sequencing applications, and what the future holds for this cutting-edge technology.

Of all types of cancer, lung cancer caused more deaths worldwide than any other type of cancer. It also causes more deaths than breast and colorectal cancers combined. Patients with the most common lung cancer, non-small cell lung cancer (NSCLC), have higher survival rates than patients with small-cell lung cancer (SCLC), but the outcomes for both remain bleak. According to the National Cancer Institute, the five-year survival rate for NSCLC between 2004 and 2010 was 20.7% compared to only 6.3% for SCLC.2

NSCLC patients also have more promising and more precise, treatment options today compared to even 10 years ago. Advances in biomarker and precision medicine have led to the development of immunotherapies and targeted novel treatments that have the potential to improve patient outcomes. In the United States, the FDA has approved dozens of biomarker-driven therapies for NSCLC, including ALK, EGFR, and ROS1 inhibitors. Meanwhile, more than 1,200 treatments are in development.

Discover the latest trends in precision medicine for NSCLC in this white paper